MBMarc A. Brouwer

Marc A. Brouwer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marc A. Brouwer has a total of 383 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PCSK9-targeting therapies and mortality: a systematic review and meta-analysis of randomized trials

    by Eliano P Navarese, Eleonora Ruscio, Haixiang Zheng, Felicita Andreotti, Victor Aboyans, Jacek Kubica, Klaudyna Grzelakowska, Timothy D Henry, Marc Brouwer, Gregg W Stone, et al.

    Aims: To evaluate the association of proprotein convertase subtilisin/kexin type 9 (PCSK9)-targeting therapies with mortality and cardiovascular events in stable or clinically stabilized randomized trial populations. Methods and results: We systematically reviewed randomized trials comparing alirocumab, evolocumab or inclisiran with placebo or active control. The review was registered in PROSPERO (CRD420261395609). Treatment effects were pooled as incidence rate ratios (IRRs) using random-effects models. The primary outcome was all-cause mortality. Prespecified subgroup analyses were based on trial-level known atherosclerosis status, as defined by enrolment criteria. Thirty-two trials enrolled 77 178 participants. Individual atherosclerosis status could not be determined beyond trial-level eligibility criteria. Mortality estimates were predominantly informed by large cardiovascular outcome trials. All-cause mortality was lower with PCSK9-targeting therapy (IRR 0.88, 95% CI 0.82–0.95). Estimates favoured PCSK9-targeting treatment in both trials requiring known atherosclerosis for enrolment (IRR 0.90, 95% CI 0.83–0.98) and trials without such an enrolment requirement (IRR 0.78, 95% CI 0.62–0.97; interaction P = 0.21). PCSK9-targeting treatment additionally reduced myocardial infarction, stroke, and coronary revascularization rates. Leave-one-out estimates remained directionally consistent. Conclusion: PCSK9-targeting therapies were associated with lower all-cause mortality and fewer ischaemic events across trial populations.

  • Open Access

    Automated Cardiac Arrest Detection Using Wrist-Worn Photoplethysmography: External Validation in Patients With Induced Shockable Cardiac Arrest (DETECT-1b)

    by Roos Edgar, Niels T.B. Scholte, Kambiz Ebrahimkheil, Catharina E. Jansen, Rypko J. Beukema, Marc A. Brouwer, Sing-Chien Yap, Masih Mafi-Rad, Reinoud E. Knops, Eelko Ronner, et al.


  • Open Access

    A machine learning model to detect falls mimicking cardiac arrest-related collapse based on wrist-derived accelerometry: the DETECT-2 study

    by Roos Edgar, Kambiz Ebrahimkheil, Danny Meeuwsen, Maud C de Jong, Job J Herrmann, Alexander M Griffioen, Niels T B Scholte, Marc A Brouwer, Rypko J Beukema, Eelko Ronner, et al.

    Aims: In wearable-based automated cardiac arrest detection technology, photoplethysmography (PPG) is the most commonly used sensor to detect the absence of pulsations. To minimize false-positive cardiac arrest alerts, accelerometry signals are often used for the detection of ongoing movement. We conducted the DETECT-2 study to develop an accelerometer-based machine learning model for the detection of cardiac arrest-related collapse, which is often a first manifestation of cardiac arrest. Methods and results: Healthy volunteers simulated cardiac arrest-related collapses through sudden and soft falls without subsequent movement. Accelerometer signals were collected using the CardioWatch wristband; video recordings were made as a reference. An accelerometer-based gradient boosting model (GBM) for fall detection was trained (70%) and tested (30%). The primary endpoint was the sensitivity for the detection of falls; secondary endpoints were false-positive fall alerts. Nineteen participants performed 567 falls. In the training set (n =13; 388 falls), the sensitivity of the GBM was 99.2% (95% confidence interval [CI] 98–100%], with four false positives. In the test set (n = 6; 179 falls), sensitivity was 96.1% (95% CI 92–98%), with two false positives. For sudden falls (n = 120) and soft falls (n = 59), sensitivities were 100% (95% CI 96–100%) and 88.1% (95% CI 76–95%) in the test set (P < 0.001), respectively. Conclusion: Using accelerometry data from the CardioWatch, sudden and soft falls that mimic cardiac arrest-related collapse can be accurately detected. The next step in the development of automated cardiac arrest detection is the integration of accelerometer signals into the existing PPG-based model, with the aim of reducing false positives and increasing sensitivity in everyday use.

  • Open Access

    Diagnostic performance of the basic and advanced life support termination of resuscitation rules: A systematic review and diagnostic meta-analysis

    by Joris Nas, Geert Kleinnibbelink, Gerjon Hannink, Eliano P. Navarese, Niels van Royen, Menko-Jan de Boer, Lars Wik, Judith L. Bonnes, Marc A. Brouwer


  • Open Access

    Effect of Face-to-Face vs Virtual Reality Training on Cardiopulmonary Resuscitation Quality

    by Joris Nas, Jos Thannhauser, Priya Vart, Robert-Jan van Geuns, Hella E. C. Muijsers, Jan-Quinten Mol, Goaris W. A. Aarts, Lara S. F. Konijnenberg, D. H. Frank Gommans, Sandra G. A. M. Ahoud-Schoenmakers, et al.

    Cardiac arrest constitutes a major health care problem, with more than 300 000 deaths annually in the United States alone.1 Early automated external defibrillator (AED) use and high-quality cardiopulmonary resuscitation (CPR) are important determinants of survival.2-6 However, most individuals with cardiac arrest do not receive any form of bystander CPR, which may be because most civilians are not currently trained in CPR.2,3,7-10 Therefore, increasing awareness, willingness, and capability to perform CPR is promoted as a key issue in international practice guidelines and by leading health care authorities.11-17


  • Open Access

    Meta-Analysis Comparing Cardiac Arrest Outcomes Before and After Resuscitation Guideline Updates

    by Joris Nas, Ruben Te Grotenhuis, Judith L. Bonnes, José M. Furlaneto, Niels van Royen, Joep L.R.M. Smeets, Menko-Jan de Boer, Eliano P. Navarese, Marc A. Brouwer


  • Open Access

    Exercise and myocardial injury in hypertrophic cardiomyopathy

    by G Etienne Cramer, D H Frank Gommans, Hendrik-Jan Dieker, Michelle Michels, Freek Verheugt, Menko-Jan de Boer, Jeannette Bakker, Michael A Fouraux, Janneke Timmermans, Marcel Kofflard, et al.

    Objective Troponin and high signal intensity on T2-weighted (HighT2) cardiovascular magnetic resonance imaging (CMRi) are both markers of myocardial injury in hypertrophic cardiomyopathy (HCM). The interplay between exercise and disease development remains uncertain in HCM. We sought to assess the occurrence of postexercise troponin rises and its determinants. Methods Multicentre project on patients with HCM and mutation carriers without hypertrophy (controls). Participants performed a symptom limited bicycle test with hs-cTnT assessment pre-exercise and 6 hours postexercise. Pre-exercise CMRi was performed in patients with HCM to assess measures of hypertrophy and myocardial injury. Depending on baseline troponin (< or >13 ng/L), a rise was defined as a >50% or >20% increase, respectively. Results Troponin rises occurred in 18% (23/127) of patients with HCM and 4% (2/53) in mutation carriers (p=0.01). Comparing patients with HCM with and without a postexercise troponin rise, maximum heart rates (157±19 vs 143±23, p=0.004) and maximal wall thickness (20 mm vs 17 mm, p=0.023) were higher in the former, as was the presence of late gadolinium enhancement (85% vs 57%, p=0.02). HighT2 was seen in 65% (13/20) and 19% (15/79), respectively (pConclusions Postexercise troponin rises were seen in about 20% of patients with HCM, almost five times more frequent than in mutation carriers. HighT2 on CMRi may identify a group of particularly vulnerable patients, supporting the concept that HighT2 reflects an active disease state, prone to additional injury after a short episode of high oxygen demand.


  • Open Access

    Rationale and design of the Lowlands Saves Lives trial: a randomised trial to compare CPR quality and long-term attitude towards CPR performance between face-to-face and virtual reality training with the Lifesaver VR app

    by Joris Nas, Jos Thannhauser, Priya Vart, Robert-Jan van Geuns, Niels van Royen, Judith L Bonnes, Marc A Brouwer

    Introduction Layperson cardiopulmonary resuscitation (CPR) is a key aspect in the chain of survival after cardiac arrest. New, low-cost, easily accessible training methods such as virtual reality (VR) training with a smartphone application may reach broader populations, but data on CPR performance are scarce. Methods and analysis The Lowlands Saves Lives trial is a prospective randomised open-blinded end-point evaluation study, comparing two 20 min CPR training protocols: standardised, certified instructor-led face-to-face training complying with current education guidelines (using Laerdal Little Anne manikins), and VR training, using the UK Resuscitation Council endorsed Lifesaver VR app. In the latter, chest compressions are practiced on a pillow. During VR training, participants learn to resuscitate by completing a filmed CPR scenario while wearing VR goggles and headphones. Eligible for inclusion are adult attendees of Lowlands Science, a specific section of the 3-day Lowlands music festival (50 000 attendees), dedicated exclusively to science. Following the training, all participants will perform a CPR test on a Laerdal Resusci Anne QCPR manikin. Primary outcome measures are depth and rate of chest compressions, measured using CPR manikins. The key secondary outcome is overall CPR performance, with real-time examination (blinded for study group) of all items of a European Resuscitation Council endorsed checklist, and evaluation of a sample of videotaped CPR tests by a blinded event committee. Given the unique setting of a festival, the primary additional analysis will address the impact of alcohol levels on CPR quality parameters and overall performance. Follow-up questionnaires will evaluate the attitude towards performing CPR. This unique study may provide important insights into innovative CPR training methods, factors that impact CPR performance and the impact on long-term attitude towards resuscitation. Ethics and dissemination This study received approval from the research ethics committee of the Radboudumc. All participants will provide written informed consent. The results of this study will be published in peer-reviewed journals and presented at (inter)national conferences. Trial registration number ClinicalTrials.gov registry (NCT04013633).


  • Cardiac troponin I is present in plasma of type 1 myocardial infarction patients and patients with troponin I elevations due to other etiologies as complex with little free I

    by Xander M.R. van Wijk, Stijn Claassen, Nicholas S. Enea, Pu Li, Samuel Yang, Marc A. Brouwer, G. Etienne Cramer, Robert Zuk, Kara L. Lynch, Alan H.B. Wu


  • Open Access

    Multi‐Site Coronary Vein Sampling Study on Cardiac Troponin T Degradation in Non–ST‐Segment–Elevation Myocardial Infarction: Toward a More Specific Cardiac Troponin T Assay

    by Sander A. J. Damen, Wim H. M. Vroemen, Marc A. Brouwer, Stephanie T. P. Mezger, Harry Suryapranata, Niels van Royen, Otto Bekers, Steven J. R. Meex, Will K. W. H. Wodzig, Freek W. A. Verheugt, et al.

    Background: Cardiac troponin T ( cTnT ) is seen in many other conditions besides myocardial infarction, and recent studies demonstrated distinct forms of cTnT . At present, the in vivo formation of these different cTnT forms is incompletely understood. We therefore performed a study on the composition of cTnT during the course of myocardial infarction, including coronary venous system sampling, close to its site of release. Methods and Results: Baseline samples were obtained from multiple coronary venous system locations, and a peripheral artery and vein in 71 non– ST ‐segment–elevation myocardial infarction patients. Additionally, peripheral blood was drawn at 6‐ and 12‐hours postcatheterization. cTnT concentrations were measured using the high‐sensitivity‐ cTnT immunoassay. The cTnT composition was determined via gel filtration chromatography and Western blotting in an early and late presenting patient. High‐sensitivity ‐ cTnT concentrations were 28% higher in the coronary venous system than peripherally (n=71, P <0.001). Coronary venous system samples demonstrated cT n T‐I‐C complex, free intact cTnT , and 29 kD a and 15 to 18 kD a cTnT fragments, all in higher concentrations than in simultaneously obtained peripheral samples. While cT n T‐I‐C complex proportionally decreased, and disappeared over time, 15 to 18 kD a cTnT fragments increased. Moreover, cT n T‐I‐C complex was more prominent in the early than in the late presenting patient. Conclusions: This explorative study in non– ST ‐segment–elevation myocardial infarction shows that cTnT is released from cardiomyocytes as a combination of cT n T‐I‐C complex, free intact cTnT , and multiple cTnT fragments indicating intracellular cTnT degradation. Over time, the cT n T‐I‐C complex disappeared because of in vivo degradation. These insights might serve as a stepping stone toward a high‐sensitivity‐ cTnT immunoassay more specific for myocardial infarction.